本页面由Tiger Trade Technology Pte. Ltd.提供服务

Allogene Therapeutics Inc.

2.17
-0.0800-3.56%
盘后2.170.00000.00%19:54 EDT
成交量:1,028.95万
成交额:2,199.80万
市值:7.49亿
市盈率:-2.83
高:2.20
开:2.16
低:2.04
收:2.25
52周最高:4.46
52周最低:0.9842
股本:3.45亿
流通股本:2.75亿
量比:1.69
换手率:3.74%
股息:- -
股息率:- -
每股收益(TTM):-0.7663
每股收益(LYR):-0.8652
净资产收益率:-52.32%
总资产收益率:-25.97%
市净率:2.68
市盈率(LYR):-2.51

数据加载中...

2026/05/28

重要事件披露

Form 8-K - Current report
2026/05/15

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/15

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/13

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/13

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/13

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/05/13

重要事件披露

Form 8-K - Current report
2026/04/23

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/04/21

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/04/15

重要事件披露

Form 8-K - Current report
2026/04/13

重要事件披露

Form 8-K - Current report
2026/04/13

重要事件披露

Form 8-K - Current report
2026/04/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/03/16

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/03/16

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/03/12

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2026/03/12

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2026/03/12

重要事件披露

Form 8-K - Current report
2026/03/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities